Navigation Links
Maher Law Firm Warns Avandia Users - NY Times Reports - FDA Recommends Recall of Avandia
Date:2/26/2010

According to the New York Times, hundreds of people taking the type-2 diabetes drug Avandia® suffer heart attacks and heart failure as result of its use. For more information, contact the Maher Law firm.

(PRWEB) February 26, 2010 -- Maher Law Firm attorneys are investigating possible Avandia® claims. Contact an experienced personal injury lawyer – one familiar with Avandia®’s potentially fatal side effects – if you or a loved one has experienced heart problems after Avandia® use.

The article, published in the Friday edition (02/19/2010), cites confidential government reports stating that if Avandia® users were instead treated with Actos, a similar pill, about 500 heart attacks and 300 cases of heart failure would be averted each month.

An internal Food and Drug Administration (FDA) report recommends Avandia®, or “rosiglitazone” be removed from the market. The authors, Dr. David Graham and Dr. Kate Gelperin, both urge Avandia®’s withdrawal.

According to the New York Times, the reports have ignited debate within the FDA as to what to do about Avandia®. While some officials support its withdrawal, others believe more testing is needed.

What is Avandia®?
Avandia®, or rosiglitazone, is a popular prescription drug, manufactured by the U.K. pharmaceutical company, GlaxoSmithKline, used to treat “type-2” or “adult-onset” diabetes.

Avandia® was once one of the biggest-selling drugs in the world. Driven in part by a multimillion-dollar advertising campaign, sales were $3.2 billion in 2006. However, after a 2007 study by a Cleveland Clinic cardiologist linked the drug to heart problems prompting an FDA warning, sales plummeted. A committee of independent experts found in 2007 that Avandia might increase the risk of heart attack but recommended that it remain on the market, and an FDA oversight board voted 8 to 7 to accept that advice.

FDA Urges Patients Not to Discontinue Avandia® Use
The FDA said Monday that for now, patients should not stop taking Avandia® without first speaking with their healthcare professional. Patients should discuss any questions or concerns with their physician. Report any side effects to FDA’s MedWatch program.

Senate: Maker Should Have Warned Patients
Senate investigators concluded that GlaxoSmithKline should have warned patients earlier of Avandia®’s potential side effects. The bipartisan multiyear Senate investigation states GlaxoSmithKline failed to warn patients years earlier that Avandia was potentially deadly.

“Instead, G.S.K. executives attempted to intimidate independent physicians, focused on strategies to minimize or misrepresent findings that Avandia may increase cardiovascular risk, and sought ways to downplay findings that a competing drug might reduce cardiovascular risk,” concludes the report, which was overseen by Senator Max Baucus, a Montana Democrat, and Senator Charles E. Grassley, an Iowa Republican.

Avandia lawyer

Contact an experienced personal injury lawyer – one familiar with Avandia®’s potentially fatal side effects – if you or a loved one has experienced heart problems after Avandia® use.

###

Read the full story at http://www.prweb.com/releases/PossibleAvandiaRecall/02/prweb3642334.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. YazTalk Warns Women of Life Threatening Side Effects
2. FDA CONSUMER HEALTH INFORMATION: FDA Warns Consumers About Unsafe Counterfeit Alli
3. Security Choice Warns Against Dangers of Carbon Monoxide
4. FDA Warns Public of Continued Extortion Scam by FDA Impersonators
5. Patients Medical Warns Against The Manhattan Diet
6. Physicians Coalition for Injectable Safety Warns Buttock-Boosting Injections Risky and Deadly
7. Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America
8. National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis
9. National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis
10. Hissey Kientz, LLP Warns Birth Control Pill Users Of Increased Health Risks To Those Who Have Or Are Taking YAZ or YASMIN
11. Throw a Yellow Flag on Football-related Head Injuries, Warns the Harvard Mental Health Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
(Date:10/12/2017)... ... 12, 2017 , ... On Saturday, October 21, the Health & Wellness Center ... to raise money for the American Heart Association Heart Walk. Teams of up to ... together to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... wound care advancements to physician colleagues, skilled nursing facility medical directors and other ... Treacherous Waters of Wound Care." , "At many of these conferences we get ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
Breaking Medicine Technology: